Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities

Executive Summary

Opdivo first-quarter sales were still strong at $1.1bn, largely driven by lung cancer use and helping to drive overall performance, but potential approval of Merck's competing Keytruda with chemotherapy in first-line lung cancer is right around the corner.

You may also be interested in...



2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi

PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.

1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva

Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.

AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind

Though momentum is building for IDO/PD-1 combos, it's still early days for new immunotherapy programs. Clinicians and investors weigh in on the latest data from the American Association for Cancer Research meeting and the state of the immuno-oncology field.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098635

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel